Cytochrome P450-Activated Prodrugs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Guengerich FP . Human cytochrome P450 enzymes. In: Cytochrome P450: Structure Mechanism and Biochemistry. Ortiz de Montellano PR (Ed.). Kluwer/Plenum/Elsevier NY USA 377–530 (2005).
Ortiz de Montellano PR De Voss JJ. Substrate oxidation by cytochrome P450 enzymes. In: Cytochrome P450: Structure Mechanism and Biochemistry. Ortiz de Montellano PR (Ed.). Springer NY USA 183–245 (2005).
Friedman OM , MylesA, ColvinM. Cyclophosphamide and phosphoramide mustards.Adv. Cancer Chemother.1, 143–204 (1979).
Colvin M , HiltonJ. Pharmacology of cyclophosphamide and metabolites.Cancer Treat. Rep.65(Suppl. 3), 89–95 (1981).
Mace JR , KeohanML, BernardyHet al. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin. Cancer Res. 9, 5829–5834 (2003).
Roy P , YuLJ, CrespiCL, WaxmanDJ. Development of a substrate activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.Drug Metab. Dispos.27, 655–666 (1999).
Legha SS . Current therapy for malignant melanoma.Semin. Oncol.16, 34–44 (1989).
Reid JM , KuffelMJ, MillerJK, RiosR, AmesMM. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2 and CYP2E1.Clin. Cancer Res.5, 2192–2197 (1999).
Friedman HS , KerbyT, CalvertH. Temozolomide and treatment of malignant glioma.Clin. Cancer Res.6, 2585–2597 (2000).
Swaffar DS , HorstmanMG, JawJet al. Methylazoxyprocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia. Cancer Res. 49, 2442–2447 (1989).
Cummings SW , GuengerichFP, ProughRA. The characterization of N-isopropyl-p-hydroxymethylbenzamide formed during the oxidative metabolism of azo-procarbazine. Drug Metab. Dispos.10, 459–464 (1982).
Komatsu T , YamazakiH, ShimadaNet al. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. Clin. Cancer Res. 7, 675–681 (2001).
Komatsu T , YamazakiH, ShimadaN, NakajimaM, YokoiT. Roles of cytochrome P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.Drug Metab. Dispos.28, 1457–1463 (2000).
Ikeda K , YoshisueK, MatsushimaEet al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin. Cancer Res. 6, 4409–4415 (2000).
Shet MS , McPhaulM, FisherCW, StallingsNR, EstabrookRW. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2.Drug Metab. Dispos.25, 1298–1303 (1997).
Rochat B , MorsmanJM, MurrayGI, FiggWD, McLeodHL. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?J. Pharmacol. Exp. Therap.296, 537–541 (2001).
Hadley WM . A Review of the Literature on Enzymatic Reduction of Nitrocompounds. Inhalation Toxicology Research Institute Lovelace Biomedical and Environmental Research Institute. Springfield VA USA 1–20 (1983).
Saulter JY , KurianJR, TrepanierLAet al. Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. Drug Metab. Dispos. 33, 1886–1893 (2005).
Wong PC , PriceWA Jr, Chiu AT et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Therap.255, 211–217 (1990).
Stearns RA , MillerRR, DossGAet al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab. Dispos. 20, 281–287 (1992).
Stearns RA , ChakravartyPK, ChenR, ChiuSH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.Drug Metab. Dispos.23, 207–215 (1995).